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Abstract 
Effect of Collagen type lll coated electrospun scaffolds on apoptosis of 
breast cancer cells 
Jasthi Sai Mounica 
Susan W. Volk, V.M.D., Ph.D. 
Breast cancer arises from the epithelial or the connective tissue components of the breast. Breast 
cancer is the most commonly diagnosed cancer in women, with about half a million women dying 
because of the disease each year. Local recurrence (return of cancer in the area of primary 
diagnosis) and metastasis (spread of cancer to other locations in the body) are major challenges 
associated with breast cancer, leading to significant mortality and morbidity in patients. Although 
death is due to metastasis, local recurrence is a gateway towards metastasis. Therefore, there 
arises a need for targeted therapeutic treatments to treat local recurrence and ultimately 
metastasis in breast cancer patients. In this project, we have developed novel, electrospun 
scaffolds to function as a therapeutic strategy for breast cancer, based on the wound healing-
fibrosis-cancer progression triad (WHFC).  
Collagen deposition and remodeling command a pivotal role in the WHFC. Previous work from 
the Volk Lab (University of Pennsylvania) supports a role for Collagen type lll (Col 3) in the WHFC 
triad. Notably, their data show that Col 3 deficiency promotes tumor growth and metastases, 
promotes proliferation, inhibits apoptosis of breast cancer cells, and fosters a procarcinogenic 
stroma by regulating collagen, myofibroblast density, and alignment. Based on this data and 
xiii 
 
other research which shows that post-surgical wound healing response in breast 
resection/biopsy sites drives aggressive tumor behaviors, we hypothesized that application of   
Col 3 coated biomaterials to breast cancer resection sites would potentially promote an optimal 
wound healing response, would suppress aggressive breast cancer behavior, and invoke a pro-
apoptotic response in residual breast cancer cells. By being able to do so, such biomaterials would 
reduce morbidity and mortality in breast cancer patients by preventing local recurrence and 
breast cancer metastasis. Additionally, this non-toxic approach would decrease morbidity by 
decreasing the need for more toxic adjuvant therapies such as radiation or chemotherapy that 
are currently used to treat breast cancer. Biomaterials have played an important role in 
improving quality of life for breast cancer patients by maintaining cosmesis in the treated breast 
and, therefore, a biomaterial that could improve healing and aesthetic outcome while controlling 
tumor behavior would provide a unique advantage to those commercially available. In the scope 
of this project, we focused our investigation on in vitro assessment of the ability of Col 3 coated 
electrospun (fibrous) biomaterials to induce apoptosis of a human triple negative breast cancer 
(TNBC) cell line (MDA-MB-231). In this investigation, we determined if the architectural makeup 
of these fibrous scaffolds, in terms of fiber orientation, would have a further effect on breast 
cancer cell morphology and ultimately on breast cancer cell apoptosis. Lastly, we assessed if         
Col 3 coated substrates could induce apoptosis in other cancer cell types. 
To initially assess apoptosis, MDA-MB-231s were seeded onto coverslips (1.13 cm2 surface area; 
48 hours) coated with equal amounts of diluted recombinant Col 3 (1 µg/cm2) and Col 1                      
(1 µg/cm2). Apoptosis was induced with 1 µM Staurosporine (24 hours). MDA-MB-231 cells 
cultured on Col 3 coated cover slips exhibited a significantly higher level of apoptosis compared 
xiv 
 
to those on Col 1 (p=0.0184). To determine if Col 3 could induce apoptosis if incorporated into a 
clinically applicable biomaterial to be used in breast cancer excisional biopsy sites, we followed 
up our previous experiments by conducting similar apoptosis studies on MDA-MB-231 cells 
seeded onto recombinant Col 3 and Col 1 (control)-coated aligned Є-Polycaprolactone (PCL) 
electrospun fibrous scaffolds. We found that Col 3 coated aligned PCL scaffolds resulted in 
significantly higher levels of apoptosis in MDA-MB-231 cells compared to Col 1 controls 
(p=0.0067). To investigate if the fiber orientation of the scaffolds affected cell morphology, we 
obtained SEM images of uncoated and Col 3 coated aligned and unaligned PCL scaffolds, both 
with and without MDA-MB-231 cells cultured onto them. We performed two complimentary 
methods to examine fiber orientation in these scaffolds: OrientationJ and circular variance 
analysis (MATLAB).  In both cases, unaligned meshes showed circular variance closer to 1, while 
aligned meshes showed values close to 0 (aligned vs. unaligned; uncoated: p=0.0064, Col 3-
coated: p=0.0016). This analysis also proved to us that our collagen coating protocol did not alter 
the alignment of the underlying PCL fibers. We further performed elongation analysis on          
MDA-MB-231 cells seeded onto uncoated and Col 3 coated aligned and unaligned scaffolds. We 
found that aligned fibers promoted a change in cancer cell morphology associated with 
aggressive cancer phenotype (highly elongated cells), while unaligned fibers appeared to restrict 
this phenotype (stellar like cells). The elongation of the cells was analyzed using Axis ratio (aspect 
ratio of cellular length to cellular width) and showed that both uncoated and Col 3 coated aligned 
fibers resulted in cells with a significantly higher elongation than uncoated and Col 3 coated 
unaligned fibers respectively (uncoated: p=0.0099, Col 3 coated: p=0.0084). This suggests that 
the ability of unaligned scaffolds to limit the aggressive cancer phenotype is a response of the 
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seeded cells to the fiber orientation (possibly through limiting contact guidance). Based on these 
experiments, we decided to check if unaligned PCL scaffolds would potentiate Col 3 induced 
apoptosis of breast cancer cell line. It is possible that the alteration of normal 
mechanotransduction in elongated (associated with aggressive phenotype) cancer cells, where 
they convert mechanical signals to biochemical signals, would affect their apoptotic ability. To 
test this hypothesis, we conducted preliminary comparative studies on MDA-MB-231 cells on    
Col 3 coated aligned and unaligned PCL scaffolds and found that Col 3 coated unaligned PCL 
scaffolds resulted in a significantly higher apoptosis than Col 3 coated-aligned PCL scaffolds 
(p=0.0066). Finally, we hypothesized that Col 3-based therapies might be effective in controlling 
other cancer types. To test this hypothesis, we examined if Col 3 could induce significant 
apoptosis in other cancer cell lines. Col 3-coated cover slips promoted significantly higher levels 
of apoptosis (p=0.0392) in human lung carcinoma cell line A549, than those seeded onto Col 1- 
coated cover slips (control). 
Therefore, our data suggests that Col 3-coated fibrous biomaterials with an unaligned fiber 
orientation significantly promote breast cancer cell apoptosis, thereby providing us with a novel 
and safe method to potentially control clinical outcomes in breast cancer patients. Our results 
also suggest that these Col 3-containing substrates should be further investigated for use in 
controlling additional (non-breast) cancers.   
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CHAPTER 1: INTRODUCTION 
1.1 Background 
1.1.1 Cancer: General Statistics 
Cancer, a term used to describe related diseases characterized by uncontrolled growth of 
abnormal cells, is the second leading cause of disease-related deaths globally. The World Health 
Organization (WHO), in its most recent global report on cancer, reported an annual incidence of 
14 million new cases and 8.2 million cancer-related deaths (2012) and predicted that the 
number of newly diagnosed cases each year will increase to approximately 22 million in the 
next two decades1. Breast cancer is the most commonly diagnosed cancer in women, with more 
than half a million women dying worldwide annually2. 
1.1.2 Breast Cancer: Major challenges 
Breast cancer arises from the epithelial components (ducts and lobules) or the connective 
tissue of the breast. If malignant, the primary breast cancer (the tumor confined to the breast) 
may spread, or metastasize, to distant regions of the body. Surgical removal of the primary 
tumor constitutes a mainstay of therapy for the breast cancer patient. In recent years, breast 
conservation surgery, which involves surgically removing a part of the breast tissue as opposed 
to complete removal in a mastectomy, has gained in popularity. The therapy seeks to achieve a 
balance between optimal locoregional control of the disease and minimized tissue resection, to 
provide the patient with both long-term survival and good cosmetic benefits3. Its effectiveness 
for local treatment of invasive breast cancer has been well established and has also been 
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credited for providing patients with a better quality of life than traditional mastectomy4,5. 
However, significant challenges are faced by the breast cancer patient during treatment for 
their local and distant disease. These are: 
i) Biopsy/resection site related tissue injury: Surgical site trauma and complications related to 
healing have improved with less aggressive surgical procedures, such as breast conservation 
therapy compared to more aggressive procedures such as mastectomy5. However, with any 
surgery, there is morbidity associated with injury and additional healing complications are 
possible. Unfortunately, surgical excisions are not just a source of morbidity for cancer patients, 
but may also impact mortality as there is research to show that surgery can fuel aggressive 
cancer behavior and accelerate metastatic behavior6. This observation was demonstrated in 
vivo by a study, which showed that biopsy in rodent models of breast cancer promotes lung 
metastasis7. Even less invasive biopsy techniques such as core needle biopsies may be 
associated with an increased risk of metastasis, as mice with biopsied mammary tumors 
showed more lung metastasis than those without biopsies, in another study8. 
ii) Microscopic residual disease (persistent cancer cells after attempts to remove them) and 
local recurrence (the return of cancer in the same area where it was originally diagnosed and 
treated): In breast surgery, the surgeon attempts to resect the entire (macroscopic) tumor 
tissue and also a margin of normal tissue around it, to increase the likelihood that no cancer 
cells are left behind. During or after surgery, these outer margins of the biopsy are examined 
microscopically for the presence of residual cancer cells, as this determines further treatment 
protocols. In patients who have undergone surgical removal of breast cancer, there is risk 
associated with local recurrence due to residual microscopic disease5. The extent of risk is 
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dependent on multiple factors such as age, cancer stage, genetic factors, aggressive nature of 
the cancer etc9. But positive margins (i.e. presence of residual cancer cells) is, expectedly, a 
positive marker for increased risk of local recurrence. Local recurrence is a significant source of 
morbidity and mortality, with a five-fold increase in risk of death compared to unaffected 
patients10. This risk for local recurrence can be mitigated by further surgery (by removing more 
tissue), but this is associated with morbidity and further compromises on the cosmetic 
outcome11. Another method that surgeons often employ to prevent local recurrence, is to 
follow up surgery with radiation therapy. However, radiation therapy to prevent local 
recurrence is usually only effective if administered immediately after breast conservation 
surgery and is itself associated with significant short-term and long-term morbidity5,12. Local 
recurrence is much more difficult to control than the original tumor, because of the aggressive 
nature acquired by the residual disease. Local recurrence, coupled with post-surgery healing in 
these resection sites, paves the path for breast cancer metastases, revealing an obvious need 
for novel and safe methods for therapeutic intervention to curb local recurrence, while also 
promoting wound healing in the resection site. 
iii) Breast cancer metastases: is the spread of cancer from its original location (the breast) to 
other parts of the body. The timing of metastasis from the primary tumor site can occur a) prior 
to the initial surgery or b) following surgery and associated with the aggressive nature of 
residual microscopic disease (as explained above). Metastatic disease can be regional or 
distant. Regional metastasis is tumor spread to areas near the primary site like the chest wall, 
skin around scar tissue and lymph nodes around the armpit. Distant metastasis is the spread of 
tumor to distant organs in the body like the lungs, brain, bone etc. About 5 % of women have 
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metastatic breast cancer at the time of their initial diagnosis13. In addition to these women, 
approximately 30 % of women without known metastatic disease at the time of initial 
diagnosis, develop metastatic breast cancer at a later time point14. These numbers underscore 
an ever increasing need for targeted efforts to prevent metastatic breast cancer.  
1.1.3 Development of novel breast cancer therapies based on the wound healing-fibrosis-
cancer (WHFC) triad  
 
A cell’s surrounding biophysical, biochemical and mechanical environment, also known as the 
microenvironment, plays a critical role in directing cellular activities and fate. Understanding 
the role of individual components of the microenvironment (additional cell types, extracellular 
matrix (ECM) and signaling molecules), will allow us to direct desirable cell responses, such as 
promoting optimal healing or suppressing aggressive cancer behaviors. The fact that many of 
the same proteins and cells become dysregulated during pathologic, failed, or fibrotic tissue 
repair and during tumor metastasis, has contributed to the reference of tumors as ‘wounds that 
do not heal’. By leveraging this knowledge to the tumor microenvironment, it may be possible 
to apply these findings to engineer optimal healing and anti-tumor environments to achieve 
superior clinical outcomes.  
The view that cancers are wounds that do not heal and the tightly regulated relationship 
between cancer and wounds has been recognized by the WHFC triad15,16. The triad signifies that 
many of the same cell types, soluble proteins, and ECM elements regulate both fibrosis and 
tumor progression15,16. Cell behaviors associated with poor quality of healing in 
biopsy/resection sites have been recognized to drive aggressive behaviors of any microscopic 
residual tumor cells left after excision, causing local recurrence and ultimately metastases 
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(Fig.1.1.3 represented diagrammatically below). There are multiple similarities between the 
mechanisms regulating chronic fibrosis and tumor progression and are discussed in the next 
chapter. This concept suggests that creating a pro-healing, anti-tumor microenvironment 
through tissue engineering strategies may effectively improve cancer patient outcomes. 
 
Fig.1.1.3. (Left panel) Primary breast cancer site treated with surgery. (Center panel) Post-
operative healing and scarring drives aggressive behavior of any residual tumor cells, which 
causes (Right panel) local recurrence of the tumor, and ultimately leads to cancer metastases to 
other secondary locations in the body. 
1.1.4 Summary of related research by the Volk lab  
A major goal of the Volk Laboratory at the University of Pennsylvania School of Veterinary 
Medicine is understanding how the extracellular matrix (ECM; non-cellular components like 
proteins, secreted by cells into surrounding medium) regulates cell behaviors in regenerative 
and tumor microenvironments. More recently, their work has focused on the role of Collagen 
type III (Col 3) in regulating physiologic and pathophysiologic responses associated with events 
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of the wound healing, chronic fibrosis, cancer triad. In their 2011 publication defining a role for 
Col 3 in cutaneous wound healing, their data showed that diminished Col 3 promotes 
differentiation of myofibroblasts, the main cellular effectors of scar tissue formation in healing 
tissues17. Their data revealed that fibroblasts (dermal) isolated from Col 3-deficient embryos 
(Col 3 +/– and Col 3 –/–) showed increased myofibroblast differentiation compared to those 
isolated from wild-type (Col 3 +/+) embryos and that there was an increased density of 
myofibroblasts in wounds of Col 3-deficient (Col 3 +/-; mice which expressed ≤ 50 % Col 3 in all 
tissues when compared to littermate controls) mice compared to wild-type littermates17.  
Myofibroblasts participate in wound healing by secreting necessary ECM proteins, contracting 
the wound and by re-organizing the ECM18. After the wound has healed, the number of 
myofibroblasts in the tissue decrease and these cells eventually disappear through apoptotic 
pathways16. However, during pathological situations, the myofibroblasts persist, and this leads 
to excessive scar formation16. Not surprisingly, wounds from Col 3-deficient mice had 
significantly more scar tissue area on day 21 post wounding compared to wild-type mice17, 
supporting a role for Col 3 in limiting scar formation. Considering these observations, it can be 
hypothesized increasing Col 3 in a wound area could minimize scar tissue formation and 
improve wound healing. 
Results from a complementary study reveal that Col 3 deficiency promotes tumor growth and 
metastasis2. To test if Col 3 deficiency drives aggressive tumor behavior murine breast cancer 
cells (4T1s) were orthotopically injected (implanting tumor cells into their tissue of origin) into 
Col 3 +/−  and +/+ littermate controls2. Suggesting a tumor suppressive role for Col 3 in breast 
cancer, primary tumors in Col 3 +/− mice were observed to be twice as large as tumors in        
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Col 3 +/+ mice (on day 21) and there was nearly a threefold increase in lung metastases in           
Col 3 +/− mice compared to Col 3 +/+ littermates2. In vitro data support direct effects of Col 3 
on metastatic behaviors (adhesion, migration, and invasion) of both murine (4T1) and human 
(MDA-MB-231) breast cancer cells. Notably, significant reduction of migration and invasion was 
observed on Col 3 coated basement membranes, as opposed to Col 1 coated and 50:50 
mixtures of Col 1 and Col 3 coated membranes2. Col 3 deficiency was also determined to 
promote proliferation and inhibited apoptosis of breast cancer cells both in vitro and in primary 
tumors in vivo2. Finally, Col 3 deficiency promotes a procarcinogenic stroma by regulating 
collagen and myofibroblast density and alignment2. Myofibroblasts are a major cellular effector 
of desmoplasia (formation of fibrous connective tissue) in the tumor microenvironment and 
interact with cancer cells to create an environment that promotes cancer growth, local 
recurrence, and metastasis19. Increased density of stromal cancer associated fibroblasts (CAFs), 
including myofibroblasts, and the collagen-rich matrix they produce and                                     
remodel, are associated with poor outcomes in breast cancer patients20-26.20,21,22,23,24,25,26                                                  
Recent work suggests that collagen organization is at least as important as density in 
modulating breast cancer behavior. Collagen alignment provides a more direct pathway for 
tumor cell migration, thereby promoting invasion to nearby tissues (metastasis)26,27. Consistent 
with Col 3/s tumor suppressive role and regulation of matrix organization, tumors from           
Col 3 +/− mice contained more mature and aligned collagen fibers than the tumors from           
Col 3 +/+ mice2. Also, at the tumor border, collagen fibers exhibited a more invasive phenotype, 
by showing an alignment perpendicular to the tumor border in Col 3 +/− mice compared to that 
seen in Col 3 +/+ mice2. Based on these observations, we hypothesized that Col 3-coated 
8 
 
biomaterials made of unaligned fibers, if applied to a region with residual microscopic tumor, 
could potentially suppress aggressive behavior and eliminate the microscopic tumor burden 
through increased apoptosis, thereby preventing local recurrence and ultimately metastases. 
Given the established role of Col 3 in the breast cancer microenvironment, it is not surprising 
that tumor resection is associated with an increased incidence and volume of tumor recurrence 
in Col 3 +/- mice compared to wild-type littermates and that delivery of recombinant Col 3 at 
the time of orthotopic injection inhibits aggressive breast cancer behavior in vivo, by decreasing 
tumor permissive stroma.  
In conclusion, by taking into consideration previous research on the effect of Col 3 on the 
regenerative microenvironment and the tumor microenvironment, we hypothesize that Col 3-
coated biomaterials with an unaligned fiber orientation, if applied to an excisional or biopsy 
region, will suppressive aggressive behavior of microscopic residual disease or eliminate 
residual disease by inducing tumor cell apoptosis, while simultaneously improving healing. 
1.2 Motivation 
 
As explained above, the statistics for breast cancer motivate efforts for better and targeted 
therapeutic treatments. Therefore, the goal of this project is to provide proof-of-concept that 
Col 3-coated electrospun fibrous biomaterials would be efficacious in promoting apoptosis in 
breast cancer cells, thereby decrease local recurrence in women who undergo surgical 
treatments for breast cancer. Though cancer metastasis is usually the killer, local recurrence is 
also important because it paves the way for metastasis and is associated with morbidity. 
Therefore, an effective therapeutic method to target local recurrence fulfills an urgent unmet 
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need. Currently, a majority of the biomaterials used in cancer therapeutics are employed to 
augment drug delivery to the cancer sites28. The indiscriminate, toxic nature of such treatments 
also results in a plethora of adverse side-effects. As opposed to these, Col 3 coated electrospun 
fibrous biomaterials may retain their ability to promote healing and maintain cosmesis of the 
breast while selectively eliminating breast cancer cells.   
1.3 Objectives 
i) The primary objective of this thesis is to investigate whether Col 3 coating of fibrous 
biomaterials can promote apoptosis in human breast cancer cells. 
ii) The secondary objective of this thesis is to investigate if fiber alignment (aligned versus 
unaligned) of Є-Polycaprolactone (PCL) electrospun scaffolds is important in biomaterial design. 
iii) The final objective of this thesis is to investigate whether Col 3-coated substrates would be 
efficacious for inducing apoptosis in other cancer types.   
In the following chapter, each of the literary aspects of the project will be discussed in required 
detail. 
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter provides literature review conducted for the various aspects of the project, 
including biomaterial interaction with the tumor microenvironment, type III and type I 
collagens, cancer cell lines utilized, the process of electrospinning fibrous scaffolds,                    
Є-Polycaprolactone scaffolds, apoptosis and ways to induce apoptosis, Staurosporine- induced 
apoptosis, caspase 3 signaling, scanning-electron and fluorescence microscopy. 
2.1 Biomaterial interaction with the cell and tumor microenvironments 
Biomaterial engineering is an amalgamation of biological and material sciences. Fibrous 
scaffolds (biomaterials) have been the focus of worldwide research in therapeutic strategies for 
various diseases29. On a cellular level, all biomaterials achieve their intended purpose by 
manipulating one or more elements of the cellular microenvironment. The cellular 
microenvironment is made up a myriad of factors which have a direct or indirect effect on the 
behavior of the cell through biochemical, biophysical or other pathways30. These factors usually 
include non-cellular components like the extracellular matrix and its elements, other homotypic 
or heterotypic cells surrounding the single cell, bioactive agents (like cytokines, growth factors, 
hormones, etc.), the cell stroma, and forces exerted by the interaction of the cell with the 
stroma30. In a similar fashion, biomaterials used in cancer studies are made to interact with the 
tumor microenvironment, which is composed of a plethora of non-cancerous cells (fibroblasts, 
CAFs, immune cells, vascular endothelial and epithelial cells), extracellular proteins (matrix 
proteins and soluble factors such as growth factors and cytokines), as well as physical and 
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chemical parameters (for example, growth factors, oxygen, interstitial pressure) which govern 
an individual tumor cell’s behavior and ultimately influence the tumor’s progression and 
metastasis31. In particular, the importance of biochemical and biophysical ECM properties on 
the regulation of tumor progression and metastasis has increased in recent years. Research also 
supports that during tumor progression, ECM components regulate the cell phenotype by 
creating tensional forces in the matrix or by making changes to the spatial orientation of the 
matrix fibrils. In response, cells make changes to their cytoskeleton, by a process called contact 
guidance32 (discussed in detail in Sec. 2.5.3), which is translated into biochemical signals that, in 
turn, alter the cell’s gene and protein expression and ultimately affect the migratory and 
metastatic potential of the tumor cell. This phenomenon holds true for cells grown on 
engineered biomaterials, which are designed to mimic or replace the native ECM of the cells. 
Many recent works also report the importance of the surface topography and fiber alignment 
of biomaterials in regulating tumor cell fate (adhesion, proliferation, migration and ultimately 
tumor progression)33,34. As discussed in the first chapter, data from the Volk lab suggests that 
Col 3 regulation of the ECM tumor fate and progression is through its direct effects on tumor 
cells as well as stromal cells. In this project, we are investigating the specific effect of Col 3 
coated fibrous biomaterial scaffolds on the apoptosis of breast cancer cell line (MDA-MB-231). 
To determine the optimal scaffold design to support Col 3’s anti-tumor properties, we are also 
investigating if the fiber alignment of the scaffolds would affect the design considerations of 
such biomaterials.  
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2.2 Collagens 
2.2.1 General structure of Collagen and importance in the field of biomaterials. 
Collagen, the most abundant protein in animals, is a major component (up to 90 %) of the 
ECM35. To date, 29 genetically distinct types of collagens have been described. Collagens have a 
triple helical structure comprised of three long polypeptide chains, forming homo- or 
heterotrimeric molecules. Collagens have a distinct composition of a regularly occurring 
sequence of amino acids, with Glycine (non-polar) at every third position35. This high glycine 
content is critical for the stabilization of the triple helical form by promoting close association of 
collagen fibers and facilitation of hydrogen bonds and intermolecular cross-link formation35. 
The triple helical molecules arrange themselves to form collagen fibrils (10-300 nm), which 
further come together to form collagen fibers (0.5-3 µm; formation represented 
diagrammatically below)35. In the tumor microenvironment, collagens affect cancer cell 
polarity, migration and signaling, by making necessary changes to the biochemical and physical 
properties of the microenvironment31,32. 
Collagen based biomaterials are used extensively in wound healing applications and oncological 
reconstruction. Of the various types of collagens, only a select few are used in biomaterial 
applications. Collagen type I (Col 1), a fibril forming collagen, is the most commonly used for 
tissue engineering and wound healing purposes (discussed in section 2.2.3)36.  
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Fig.2.1.1. Steps of collagen fiber assembly. Picture adapted from B. Albert et al. (2014)35. 
2.2.2 Collagen Type ІІІ (Col 3) 
Col 3 is a homotrimeric protein made up of three α1(ІІІ) polypeptides37. Col 3 is highly 
expressed during embryonic development and is also found in a large number of post-natal 
tissues such as skin, blood vessels, gastrointestinal tract etc., where there seems to be a direct 
correlation between the relative proportion of Col 3 to Col 1 and the extensibility of the 
connective tissue38. Based upon Col 3’s expression pattern early in the course of healing of 
most tissues and organs after injury, Col 3 has been hypothesized to play an important role in 
tissue repair39. A role for Col3 in modulating bone and skin healing following injury is supported 
by previous studies by the Volk lab17,40. Col 3 plays a critical role in limiting lateralization of Col 1 
fibrils (and therefore fibril diameter). Although Col 3 is expressed to a much lesser extent in 
hard tissues such as bone and cartilage, previous studies by the Volk lab shows that Col 3 plays 
an important role in trabecular bone formation and maintenance, through its direct effect on 
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osteogenesis. Col 3 also plays a minor role in modulating fracture repair40. Mutations in the 
gene which encodes Col 3 cause vascular Ehlers-Danlos Syndrome (vEDS) in human patients17. 
Typically, these patients are not diagnosed until the third or fourth decade of life when they 
develop catastrophic failure and subsequent impaired ability to heal cardiovascular, urogenital, 
and gastrointestinal tissues, leading to premature death. In addition, they have thin, 
inextensible skin, vascular tissue irregularities, and abnormal scarring; they also display skeletal 
abnormalities, including a distinctive facial appearance, spinal deformity, scoliosis, and 
osteoporosis etc17. In the scope of this project, we are majorly concerned with the important 
role that Col 3 plays in the various steps of the WHFC triad and its potential use in therapeutic 
cancer treatments, which will be discussed in detail in sec 2.3.3.  
2.2.3 Type І collagen (Col 1) 
Col 1 is the most abundant of all the collagen types41. It is a heterotrimeric protein composed of 
two α1(І) and one α2(І) polypeptides41. Col 1 is an important component of the stromal ECM of 
normal breast tissue and the breast cancer microenvironment. Col 1 is temporally and spatially 
regulated during mammary ductal formation26. Diminished levels of the Col 1 cell surface 
receptor α2β1 integrin results in hampered mammary epithelial tubule formation and changes 
branching morphogenesis26. Increased Col 1 deposition increases risk of breast cancer 
metastases2,41. Patients with a collagen-dense breast tissue are at a four times higher risk of 
developing breast cancer than those with less dense breast tissues26. Col 1 also modulates cell 
polarity, cell-cell adhesion, and growth factor signaling in a tumor-promoting manner. In vivo 
experiments using a bi-transgenic mouse model have demonstrated the relationship between 
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increased stromal collagen deposition and a corresponding increase in mammary tumor 
initiation, progression, and ultimately lung metastasis42.  
However, despite the documented pro-carcinogenic effects of Col 1, Col 1-based biomaterials 
are commonly used in medicine, including their extensive use as dermal replacements due to 
their mechanical properties and relatively low immunogenic potential36. There are a multitude 
of Col 1 based scaffolds which are used in breast reconstruction (and other oncological 
reconstruction) therapies. In the scope of this project, Col 1 has been used as a control in 
various experiments. The response of cancer cells to substrates and scaffolds coated with   Col 3 
has been compared to similar substrates and scaffolds coated with Col 1.  
Collagen alignment has also been shown to promote cancer cell invasion at the tumor-stromal 
interface, along radially aligned collagen fibers and that tumor and tumor-promoting stromal 
cells facilitate this alignment during invasion42,26. This suggests that cells present at the tumor 
boundary reorganize their surrounding ECM by contracting and increasing alignment of 
collagen fibers, and then use these stiffer and linearized collagen fibers for tumor progression 
and ultimately metastasis26. These studies suggest that biomaterials comprised of unaligned 
collagen fibers may lead to a more anti-metastatic environment.  
2.3 Breast cancer metastasis: Role of Col 3 
2.3.1 Metastatic cancer: General definition, mechanism and challenges 
Metastatic cancer by definition is the spread of neoplastic cells from the region of the primary 
tumor to distant areas of the body. Cancer metastasis is notoriously difficult to treat and is the 
underlying cause of 90 % of all cancer-related deaths41. The process of metastasis occurs in 
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several steps and includes: local invasion, intravasation, circulation, arrest and extravasation, 
proliferation, and angiogenesis (represented diagrammatically below). 
 
Fig.2.3.1. Cellular processes associated with cancer metastases. (a-b) Cancer cells break away 
from neighboring cells of the primary tumor by compromising adhesion and clearing a path to 
move away from the primary tumor. (c) Intravasation, where the cells invade nearby lymph or 
blood vessels. (d-e) Circulation or Migration, where the cells circulate in the vessels and bind to 
metastasis favorable sites or platelets (f-g) Extravasation and Invasion, where the cells stop 
circulating and invade surrounding tissues and proliferate in secondary sites. Picture adapted 
from A. Schroeder et al. (2011)43. 
In general, treatment options for metastatic cancer include surgery, radiation, hormonal and/or 
chemotherapies, depending on the tumor type and characteristics, the extent of metastasis, 
symptoms of the patient and past treatment history44.  
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2.3.2 Breast cancer metastasis 
Breast cancer metastasis may be locoregional (to the regional lymph nodes, underlying chest 
wall) or distant (to the brain, bone, lungs and liver). This spread can happen before surgery or 
due to residual tumor cells in the body (either residual at the primary tumor or from other 
metastatic sites) after surgery. Recent data suggest that 30 % of women diagnosed with early 
stage breast cancer have aggressive disease and develop metastatic disease at some point in 
their lives14. In the United States alone, metastatic breast cancer causes 40,000 deaths every 
year and at any given time and an estimated 150,000–250,000 people are coping with 
metastatic breast cancer14. These statistics motivate efforts to develop more targeted efforts to 
treat breast cancer metastasis. 
2.3.3 WHFC triad: Role of Col 3 
The WHFC triad recognizes a co-relation between many of the mechanisms which drive wound 
healing and cancer progression i.e. many of the same cell types and ECM elements that 
promote wound healing and regeneration (using distinct signaling pathways), are dysregulated 
in chronic fibrosis and tumor progression, thus leading to the reference of tumors as “wounds 
that do not heal”16. It is therefore not a surprise that acute tissue injury associated with biopsy 
in rodent models of breast cancer promotes lung metastasis7. Common mechanisms, which 
drive the WHFC triad, are represented in the diagram below. 
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Fig.2.3.3. This illustration depicts mechanisms, which in the presence of chronic wound healing 
drive the WHFC triad, a vicious cycle between chronic fibrosis and aggressive cancer 
behavior/metastases. Adapted from B. Rybinski et al. (2014)16. 
As depicted in the diagram above, there are many commonalities in the mechanisms of poor 
wound healing which drive both chronic fibrosis and cancer metastases. In support of this 
concept, preliminary data from the Volk lab reveals that resection in Col 3 +/- mice is associated 
with an increased incidence and volume of tumor recurrence. Each of these has been described 
briefly below, with the potential role of Col 3 in regulating their occurrence: 
1) Myofibroblast differentiation: Metabolically active myofibroblasts are present in normally 
healing wound tissue, fibrotic tissue, and tumor desmoplastic tissue. However, in non-
pathological conditions (normal and regenerative healing), their presence is self-limited as 
they typically undergo apoptosis in the later stages of wound repair16. This usually results 
due to cell senescence and the resulting elimination of activated myofibroblast cells. This 
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may occur via p53, integrin related apoptosis, through cell clearance mechanisms 
conducted by natural killer cells, and/or by interferon gamma secretion. However, in 
pathological conditions like excessive scarring or tumor desmoplasia, myofibroblasts 
persistence is associated with aberrant cell clearance mechanisms and escape of apoptotic 
pathways. The ability of Col 3 loss to promote myofibroblast activation and persistence and 
increased scar formation were defined in wound healing studies by the Volk lab17. 
Subsequent studies showed that Col 3 suppression with high and low doses of a protein 
mediating limb regeneration, Newt Anterior gradient protein (nAG), induce myofibroblast 
density in cutaneous wound using rabbit hypertrophic scar model45. Given the known 
tumor-promoting role of myofibroblasts in breast cancer, these studies support the 
hypothesis that the increased incidence and volume of recurrence in Col 3-deficient mice 
compared to wild-type littermates is, at least in part, due to the induction of myofibroblast 
activation post-resection. Therefore, it can be said that diminished Col 3 fuels the WHFC 
triad in the post-resection microenvironment by promoting myofibroblast differentiation 
and a tumor desmoplastic reaction. 
2) ECM remodeling: Pathological remodeling of the ECM is known to be both the cause and 
consequence of chronic fibrosis and tumor progression16. The ECM in chronic fibrosis and 
tumor microenvironments is qualitatively and quantitatively different, in both type and 
architecture, from the ECM of non-pathological conditions, leading to distinct physical and 
biochemical properties of the ECM16. Fibrotic and desmoplastic environments are 
characterized by an increase in stiffness of the ECM16 compared to normal tissue. This 
stiffness is documented to alter cell growth, gene expression, cell proliferation, and modify 
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the bioactivity of ECM molecules (ex: releasing TGF-β), which further trigger myofibroblast 
differentiation and further stiffening of the ECM16. Therefore, a stiff ECM promotes chronic 
fibrosis in a feed-forward dependent fashion. Col 3 deficient fibroblasts secrete a more 
aligned and denser fibrillary collagen matrix2, which is associated with an increase in tissue 
stiffness and has been shown to provide a more favorable path for cancer cell migration and 
metastasis in murine breast cancer models and human patients. Therefore, we can say that 
Col 3 plays a critical role in ECM remodeling associated with both chronic fibrosis and tumor 
metastasis.  
3) Cell proliferation: A common occurrence in both tumor and chronic fibrosis, associated with 
a loss of homeostasis, is the presence of a hyperproliferative wave of cells16. In cancers, cells 
may lose their ability for controlled proliferation and continue to proliferate 
indiscriminately, thereby causing the formation of tumorous tissue. Hyperproliferative 
waves are also seen in epithelial and mesenchymal cells in fibrosis and tumor progression, 
secondary to certain mitogenic factors16.  
4) Epithelial-mesenchymal transitions: Epithelial cells may undergo a phenotypic change 
referred to as epithelial-mesenchymal transitions (EMT). In cancer, EMT is associated with 
ECM proteolysis and increased malignant cell motility, thereby rendering an ability to 
invade and metastasize16. EMT promotes a stem cell-like phenotype in malignant cells, 
which is said to result in the failure of therapeutic strategies16. While data suggests that loss 
of Col 3 in the tumor microenvironment promotes induce an EMT-like process in breast 
cancer cells2, the mechanism by which this occurs is currently under investigation.  
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From the above description, it is apparent that multiple mechanisms associated with pathology 
in wound healing also drive tumor progression and metastasis. Col 3 appears to utilize several 
of these mechanisms to promote optimal wound repair and suppress breast cancer formation 
and progression. Targeting Col 3, therefore, holds great potential as a therapeutic strategy for 
both breast cancer and wound patients alike. As suggested in the first chapter, research into an 
appropriately designed biomaterial, coated with Col 3, with an unaligned fiber orientation, if 
applied to a resection/biopsy area of primary breast cancer, could potentially improve wound 
healing in the area, while decreasing (or potentially eliminating) microscopic disease burden 
and promoting an anti-metastatic environment. 
2.4 Cancer Cell lines used in the project 
2.4.1 Human breast cancer cell line: MDA-MB-231 
MDA-MB-231 is a human breast cell line (adenocarcinoma), derived from the associated 
metastatic pleural effusion of a 51-year-old Caucasian female. MDA-MB-231 is characterized as 
a Triple-Negative breast cancer (TNBC) cell line44. Patients presenting with breast cancer have 
three distinct markers; estrogen receptor (ER), progesterone receptor (PR), and amplification of 
HER-2/Neu evaluated. Tumors not expressing these markers are characterized as Triple-
Negative. Women with TNBC have very limited treatment options, because of the lack of 
therapeutic targets. Although TNBC constitute only 10-15 % of breast cancer, they are 
considered more difficult to treat than other types and account for a disproportionate number 
of breast-cancer related deaths44. Their prognosis is often considered poor, when they do recur, 
owing to the aggressive tumor phenotypes and only have a partial response to chemotherapy. 
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TNBC patients show the worst survival rates because of increased relapse among those with 
residual disease after chemotherapy47. The MDA-MB-231 cell line has been extensively used for 
breast cancer research, especially in modelling aggressive human breast cancer behavior2,46-48 
and provides a logical choice to examine the induction of apoptosis by Col 3-containing 
biomaterials. 46,47,48 
2.4.2 Murine breast cancer cell line: 4T1 
4T1 is a transplantable murine breast cancer cell line (carcinoma)49. It is a highly invasive and 
tumorigenic cell line and is used widely in in vitro and in vivo experiments related to breast 
cancer metastasis2,49. The cell line is documented to efficiently metastasize from the region of 
the primary tumor to other parts of the mouse’s body49. The cell line grows in the anatomically 
accurate site when transplanted into syngeneic mouse models. In addition, 4T1 metastasis 
recapitulates metastasis in a manner similar to that of human breast cancer49. The cell line, 
which is syngeneic with the background strain of the Col 3 mice, has been used in experiments 
performed at the Volk lab, especially to demonstrate the direct and indirect effects of Col 3 on 
tumor cell adhesion, invasion, migration, proliferation and apoptosis2.  
2.4.3 Lung cancer cell line: A549 
A549 is a human carcinoma, hypotriploid cell line from a 58-year-old Caucasian male and was 
initiated in 1972 by Giard DJ et al., by explant culture method50. This cell line was used in our 
project, to examine whether Col 3-coated biomaterials direct apoptosis of cell lines other than 
the MDA-MB-231 breast cancer cell line. 
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2.5 Electrospinning 
2.5.1 History and principle  
Electrospinning is one of the oldest methods used for fabricating polymer-based fibrous 
biomaterials. First devised in the 1930s, the method has gained momentum over the years, 
with the ever-expanding interest in nanotechnology. Electrospinning uses the principle of static 
electrical charges51. These charges act on the molecules of a solution at a predefined density. 
This causes self-repulsion in the charges, resulting in stretching of the liquid into a fiber in the 
electric field51. These fibers are then collected using a grounded rotating or static metallic 
collection unit. In a basic electrospinning setup, there are four main components: i) a 
hypodermic hollow needle ii) a solution reservoir (usually a syringe) iii) a metallic collection 
unit, which is usually in the form of a metallic mandrel, and iv) a high voltage source51. The 
positive lead of the high voltage source is connected to the needle, while the negative lead is 
connected to the metallic collection unit. The high voltage is thereby used to eject electrically 
charged solution from the solution reservoir (syringe), through the hollow needle. This 
electrically charged solution evaporates or solidifies and collects as a web of fibers on the 
metallic collection unit (diagrammatically represented below).  
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Fig.2.5.1. A general electrospinning setup. 
The orientation, density, porosity, thickness and other physical parameters of the collected 
fibrous mesh is determined by the distance of the needle from the collection unit, the amount 
of voltage being supplied, the solution feed rate, the viscosity and other properties of the 
solution (conductivity and surface tension), humidity in the room, temperature of the room, 
and the rotating speed of the collection unit (if a rotating mandrel is being used)52. All of these 
conditions determine the final physical properties of the electrospun fibrous mesh.  
Electrospun fibrous scaffolds can be utilized to successfully mimic the ECM of native tissues53. 
Such scaffolds are known to facilitate cell growth, enable nutrient and metabolic waste 
exchange between the seeded cells and their ECM53. They also provide for a large surface area 
to deliver biochemical signals to the cells seeded onto them. Electrospinning can be performed 
using both natural and artificial polymers. Artificial polymers are, however, preferred over 
natural polymers because they tend to have a higher mechanical strength and adjustable 
biodegradability. For the purpose of our project, we have used an artificial polymer called PCL 
(Є-Polycaprolactone). 
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2.5.2 Electrospun Є-Polycaprolactone (PCL) scaffolds 
PCL was first synthesized in the 1930s. PCL is prepared by the ring-opening polymerization of 
the cyclic monomer Є -caprolactone. The polymer was over-ridden by other polymers for a few 
decades, before it made a comeback in the 2000s, owing to its superior viscoelastic and 
rheological properties54. PCL is semi-crystalline, has good solubility, a low melting point           
(59-64 °C) and excellent blend compatibility, all of which make it an ideal component of 
electrospun constructs52. In addition to these characteristics, we chose PCL for our in vitro 
experiments because of its stability in a hydrated state. PCL degrades slowly (hydrolysis), 
thereby giving us the necessary time to conduct our experimentation, without the scaffold 
undergoing degradation before fixation of the samples for analysis and quantification of 
results55. In vivo, PCL acts as a persisting structural element, typically in conjunction with 
another polymer that acts as a sacrificial agent55 (discussed in Sec 4.11). In our project, we have 
contrasted the effects of aligned and unaligned PCL fibrous scaffolds (coated with Col 3) on the 
apoptosis of MDA-MB-231 cells. Collagen coating of PCL electrospun scaffolds will be discussed 
in detail in the next chapter. By adjusting the speed of the rotating mandrel (fiber deposition 
unit), the directional orientation of the deposited fibers can be altered. Aligned fibers, as the 
name suggests, show a more organized pattern in the fibers, with the fibers mostly being 
oriented in one principal direction. On the other hand, unaligned fibers show no particular 
principal directional orientation. The methods employed to produce these scaffolds will be 
discussed in detail in the next chapter. 
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2.5.3 Effect of fiber alignment on MDA-MB-231 cell morphology and growth 
Multiple studies suggest that fiber orientation in electrospun fibrous scaffolds has an effect on 
cell growth and contact guidance32,56. In literary searches conducted for the purpose of this 
project, we did not come across other research or papers where the effect of fiber orientation 
of electrospun scaffolds on cancer cell apoptosis had been investigated. Therefore, our research 
explored this innovative approach in development of ‘smarter’ biomaterials for oncologic 
reconstruction based on biologic behaviors of breast cancer cells on aligned and unaligned 
matrices. 
During tumor progression, a major mechanism by which ECM components regulate the cell 
phenotype is by creating tensional forces in the matrix. Responding to physical cues from either 
a native ECM or engineered biomaterials, cells alter their directional migration by a process 
called as contact guidance32. To be able to migrate, tumor cells must change their morphology 
(shape and stiffness) and do so by interacting with their ECM substrate. In the first step in this 
change in morphology, the cell becomes more polarized and elongates its cell leading edge, 
which then attaches to the ECM substrate. The cell body then contracts and the ECM provides 
necessary traction for the cell to have a forward gliding movement57. Studies have shown that 
cells seeded onto unaligned fibrous scaffolds, tend to attach to multiple fibers, while cells 
seeded onto aligned fibers, grow along the length of the fibers. Two previous studies revealed 
that MDA-MB-231 show elongation of the cytoskeleton and nuclei as well as alignment along 
the fiber axis (spindle-like morphology), when seeded onto aligned PCL scaffolds, while those 
grown on unaligned PCL showed a mixture of cells with spherical (stellar-like) and elongated 
morphology58,32. These morphologic changes of cancer cell could lead to changes in the 
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mechnotransduction, a process by which cells convert mechanical forces to biochemical signals 
(ex. signaling pathways)59. Mechanotransduction has been shown to regulate key cellular 
activities including apoptosis59. An increase in cellular mechanotransduction has been shown to 
increase resistance to apoptosis59. Breast cancer cells seeded onto aligned PCL fibers 
upregulate expression of EMT-associated genes Cytokeratin 14 (Ck14), Smooth muscle actin 
(Sma), TGFβ-1 (Tgfb1), Snail, Fibroblast specific protein-1 (Fsp1) and Smad332 to a greater 
extent than those seeded onto unaligned PCL scaffolds. The upregulated expression of some of 
these proteins/markers might also make the cells resistant to apoptotic pathways, by enabling 
them to block cell death pathways at different levels (ex. the p53 integrin-regulated pathway)60 
and/or by altering integrin expression. A more elongated and migratory phenotype associated 
with the EMT progress enables the invasion of apoptosis-resistant clones, thereby promoting 
tumor invasion efficiency and apoptotic-resistant metastases58. Therefore, we hypothesized 
that unaligned (randomly-oriented) biomaterials would be preferential for oncologic 
reconstruction due to its ability to limit invasion of cancer cells into surrounding tissues and 
decrease resistance to apoptosis.   
2.6 Induction of apoptosis 
2.6.1 Caspase 3 apoptotic pathway 
Apoptosis by definition is programmed cell death. Caspases (cysteinyl aspartate proteinases) 
are mediators of apoptosis61. Caspases contain a single chain of inactive zymogens, each 
containing four domains: N-terminal prodomain, a large subunit (MW ~ 20 KD), a small subunit 
(~10 kD) and a linker region connecting these subunit regions. The subunits are separated using 
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proteolytic cleavage of caspase precursors62. Caspases are further classified as effector   
(caspase 3, 6, and 7) or initiator caspases (caspase 2, 8, 9 and 10), based on their pro-apoptotic 
functions63. Caspase 3 is an effector caspase, which on activation leads to the cleavage of a 
multitude of important cellular proteins in the nucleus, cytoplasm, and cytoskeleton. Caspase 3 
is activated by two different pathways. In the intrinsic pathway, activation occurs in the 
mitochondria, whereas in the extrinsic pathway activation occurs at the plasma membrane by 
death receptor ligation63. Since caspase 3 is considered a primary effector caspase, its 
activation is considered to be a positive marker for an irreversible commitment of the cell to 
apoptosis. Therefore, in our project, we have determined caspase 3 positivity in cells (detected 
by immunofluorescence) to quantitate induction of cancer cell apoptosis. The apoptotic 
molecular pathway is represented diagrammatically below. 
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Fig.2.7. Caspase 3 activation pathway. Intrinsic pathway: Caspase 8 initiates the mitochondrial 
pathway by cleaving tBID which promotes cytochrome c release from the mitochondria, 
followed by the formation of the apoptosome, which activates caspase 9. Active caspase 9 
further starts the activation cascade by processing caspase 3 and caspase 7. Extrinsic pathway: 
Fas ligand binds Fas and causes olgiomerization of caspase 8, using the FADD adaptor molecule. 
Activated caspase 8 subsequently activates caspase 3 by direct proteolytic activation. Adapted 
from S.Cullen et al. (2009)63. 
In our project, to investigate the mechanisms of apoptosis of cancer cell lines, several methods 
to induce apoptosis were evaluated. These methods included exposure of cells to high-
temperatures or/and starvation. However, Staurosporine was selected as an inducer of 
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apoptosis based on its consistency in inducing an apoptotic response in our cultured breast 
cancer cells. 
2.6.2 Apoptotic Stimuli: Staurosporine 
Staurosporine was used as an apoptotic stimulus in our experiments. It is known to be a potent 
PKC (Protein Kinase C) inhibitor, acting on the catalytic domain of the PKC64. It is commonly 
used to experimentally induce apoptosis in various cell lines. Currently, many cognates of 
staurosporine are being used in advance stages of clinical trials as an anti-cancer drug64. PKC is 
a phospholipid-dependent enzyme, which is calcium-activated and a major component of the 
transmembrane signaling pathway65. PKC pathway activation induces cell proliferation and 
differentiation65. Downregulation of PKC (delta) in MDA-MB-231 cells has been shown to 
promote apoptosis66. Staurosporine treatment of A549 cells altered cell morphology, consistent 
with apoptosis. Whether this staurosporine-mediated effect is mediated by PKC (alpha) 
inhibition, along with inhibition of other integrins and transmembrane proteins called                 
E-cadherins remains ill-defined67. Therefore, by using a PKC inhibitor (staurosporine), we aimed 
to stimulate apoptosis in the MDA-MB-231 and A549 cell line, in vitro. 
2.7 Immunofluorescence 
Immunofluorescence (IF) is a cell imaging technique, in which fluorescently-labeled antibodies 
are used to localize target antigens. Antibodies are labeled (conjugated) with fluorescent dyes 
called fluorophores. The fluorophore-tagged cells are then observed using a fluorescence 
microscope. The IF technique used by in the described experiments uses two antibodies 
(primary and secondary)68. The primary antibody is unconjugated (is not attached to a 
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fluorophore) and the secondary antibody, conjugated with a fluorophore, is then directed 
against the primary antibody to enable detection68.  IF protocols, in general, have the following 
steps: cell fixation, permeabilization, blocking, immunostaining with antibodies followed by 
incubation, counter staining and mounting. The antibodies and methodology used will be 
discussed in detail in the next chapter. In our project we have used IF to detect activated 
caspase 3 positivity in cells.  Shown below is an example. 
 
 
Fig.2.7. IF image showing activated Caspase 3 positivity in MDA-MB-231 cells (red staining). 
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2.8 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) is an imaging technique, which allows for extremely high 
magnification visualization of samples and specimens. In principle, a SEM microscope directs a 
highly focused beam of high-energy electrons to the surface of a solid specimen, to create an 
image of the specimen at high magnification69. By using SEM microscopy, it is possible to study 
a variety of features of the sample (ex. external morphology). General protocols for SEM 
imaging includes the following steps: fixing the sample, dehydrating the sample using increasing 
concentrations of ethanol, chemical drying, mounting, sputter coating using a metal alloy        
(ex: Gold-Palladium alloy) and imaging. The exact protocol used for our project will be discussed 
in detail in the next chapter. For the purpose of this project SEM imaging was used to observe 
PCL fiber scaffolds. In particular, this imaging technique was used to observe fiber orientation 
of our PCL scaffolds and also the morphology of breast cancer cells seeded onto them. 
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CHAPTER 3: METHODOLOGY 
3.1 Experimental Design 
Taking into consideration the objectives given in the first chapter, we designed our experiments 
in the following way (the details of the methods are discussed in further sections): 
1) To obtain the large supply of collagen needed for future biomaterial generation, we 
attempted extraction of Col 1 and Col 3 from bovine skin. A protocol to isolate collagens 
using acid digestion and pepsin digestion from bovine skin and separate Col 1 and Col 3 
from the isolated collagen, was developed from published protocols70-72. Western blot 
analysis was performed to determine if successful separation of Col 1 and Col 3 in the 
obtained collagen fractions has occurred. Although we were able to isolate collagen, we 
were not able to successfully separate the two fibrillar collagens based on differential salt 
precipitation. Given time constraints, it was decided to continue with commercially-sourced 
recombinant Col 3 and Col 1.70,71,72. 
2) Simultaneously, we developed protocols for the electrospun polymer scaffold (PCL), which 
could efficiently integrate Col 1 and Col 3. Collagen coating of PCL scaffolds was performed 
as a superior approach to electrospinning collagen and PCL composites, due to the 
extremely high collagen quantities required for the second approach. This required 
development of a deposition protocol, where recombinant Col 1 and Col 3 were coated on 
aligned PCL scaffolds and air dried in a laminar hood. The protocol to sterilize and rehydrate 
the PCL was adapted from the Mauck Lab, Perelman School of Medicine55. The amount of 
collagen to be coated was optimized accordingly. 
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3) To confirm the fiber orientation of our electrospun scaffolds, a protocol to SEM image our 
scaffolds was adapted from the Microscopy core, Perelman School of Medicine. 
4) We next determined the optimal apoptosis induction protocol. For this, we quantitated 
murine (4T1) and human (MDA-MB-231) breast cancer cell apoptosis in response to physical 
(heat and starvation) and chemical (staurosporine) stimuli. Staurosporine was selected 
based on its consistent ability to induce apoptosis in moderately dense cell cultures (≥ 20 
cells/ frame) to allow us to accurately quantify apoptosis when imaging. 
5) We then continued with preliminary tests, by plating MDA-MB-231 cells on Col 3 and         
Col 1 (collagen control) coated cover slips, while using staurosporine as an apoptotic 
stimulus. Percentage of cells undergoing apoptosis was determined by the fraction of cells 
demonstrating positive active caspase 3 immunoreactivity compared to the total number of 
cells (identified by DAPI staining) using Immunofluorescence imaging, ImageJ and 
GraphPad- Prism 7 software. 
6) To investigate our primary aim, MDA-MB-231 cells were seeded onto Col 3-coated and      
Col 1-coated PCL (aligned) scaffolds, while using staurosporine as an apoptotic stimulus. 
Percentage of cells undergoing apoptosis was determined by the fraction of cells 
demonstrating active caspase 3 immunoreactivity compared to the total number of cells 
(identified by DAPI staining) using Immunofluorescence imaging, ImageJ and GraphPad- 
Prism 7 software. 
7) Next, we evaluated whether fiber alignment of PCL scaffolds would affect cancer cell 
morphology, in terms of elongation and staurosporine-induced apoptosis. For this, 
protocols developed by the Mauck Lab were adopted to spin PCL with aligned and 
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unaligned fiber orientations53. Orientation of the fibers was confirmed using ImageJ analysis 
and circular variance analysis of SEM images. To determine if our Col 3-coating method was 
interfering with the fiber alignment of the underlying PCL, we conducted similar orientation 
analysis on Col 3-coated aligned and unaligned PCL scaffolds. SEM images were also used to 
analyze cell elongation and this was done using Axis ratios, calculated by ImageJ. Cells were 
fit with a custom ellipse on ImageJ and the ratio of the major to minor axis was calculated 
to give the axis ratio (which positively correlates with cell elongation). Apoptosis was 
assessed in MDA-MB-231 cells seeded onto uncoated and Col 3-coated aligned and 
unaligned PCL scaffolds. The percentage of cells undergoing apoptosis was determined by 
the fraction of cells demonstrating active caspase 3 immunoreactivity compared to the total 
number of cells (identified by DAPI staining) using immunofluorescence imaging and 
subsequent analysis by ImageJ and GraphPad Prism 7 software programs.  
8) To investigate our final aim, A549 cells were plated on Col 3 and Col 1 (collagen control)-
coated cover slips. Again, staurosporine was used as an apoptosis stimulus. Percentage of 
cells undergoing apoptosis was determined as described above.   
3.2 General experimental conditions 
This chapter contains the methodology for experiments performed during the course of this 
project. In this section, general tissue culture techniques used in the experiments are listed. 
Following are the conditions we used for all the experiments, unless otherwise stated: 
 All the experiments conducted using multi-well plates were done so using non-tissue 
culture treated 24 well plates (Falcon®, Corning Brand, Tewksbury, MA). 
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 For all experiments requiring Phosphate buffered saline (PBS), we used Dulbecco’s 
Phosphate buffered saline (1X) without calcium or magnesium (Medintech Inc., Corning, 
Cellgro, Manassas, VA). 
 For all the experiments which required media, we used DMEM (Dulbecco’s Modified Eagle’s 
medium; Glutamax™, Gibco, Grand Island, NY) containing D-glucose (4.5 g/l) and sodium 
pyruvate (110 mg/l), supplemented with 10 % FBS (Atlanta Biologicals, Flowery Branch, GA) 
and 1 % Pen-Strep (10,000 U/ml penicillin and 10,000 µg/ml streptomycin; Biowhittaker®, 
Lonza, Walkersville, MD). This condition was only changed in experiments where cell 
starvation was required, where DMEM with 1 % Pen-Strep, devoid of FBS was used. 
 MDA-MB-231, 4T1 and A549 cell lines were obtained from ATCC®. All cell lines were 
authenticated by morphology, growth characteristics, and biological behavior and 
confirmed negative for Mycoplasma (MycoAlert® Mycoplasma detection kit, Lonza, 
Rockland, ME) prior to cryopreservation and subsequent use by the Volk lab. 
3.3 Col 3 & Col 1 isolation  
3.3.1 Pretreatment of bovine-skin 
Bovine skin (40 g), obtained from an abattoir, was utilized as a collagen source. Hair was 
removed from the skin by depilation using Nair hair removing cream and washed thoroughly 
with distilled water. Subcutaneous fat was removed and the skin was then cut into small        
(~1-8 mm3) pieces using a scalpel blade in order to increase the surface area. The skin was 
subsequently defatted using cold acetone (Sigma, St. Louis, MO).  During this process, the 
37 
 
acetone-skin mixture was stirred (4° C).  Acetone was changed every 48 hours (3X) prior to final 
washes with cold distilled water until the pH value was 7.070,71.  
3.3.2 Extraction of acid soluble collagen 
After washing three times with cold water (5-8 ᵒC), the skin (1 gm) was then soaked in 0.5 M 
glacial acetic acid (Fisher Scientific, Fairlawn, NJ) with a solid: solvent ratio of 1:15 (w/v) for      
24 hours. The acid insoluble component was removed by filtration through bi-layered 
cheesecloth. This was repeated twice and two filtrates were obtained and later combined. The 
filtrate was then subjected to precipitation using 2.6 M NaCl (FisherScientific, Fairlawn, NJ) and 
0.05 M tris (hydroxymethyl) amino methane. 5 M NaOH in small volumes (while continuously 
checking for pH, using pH strips) was then added until the filtrate pH become 7.0.  The mixture 
was then ultracentrifuged (Optima™ L-90k Ultracentrifuge, Beckman Coulter, Fullerton, 
California), at 20,000 x g /198,000 rpm for 1 hour. The resultant pellet was re-suspended in 300 
µl of 0.5 M glacial acetic acid, by stirring on a shaker until the pellet dissolved70,71. Since the 
pellet did not dissolve completely after 48 hours, gentle mechanical disruption, using a glass 
rod, was used to facilitate dissolution. 
3.3.3 Extraction of pepsin soluble collagen 
The acid-insoluble skin residue remaining after filtration was used for pepsin-soluble collagen 
extraction. The skin was soaked in 0.5 M glacial acetic acid with an acid solvent ratio of          
1:15 (w/v) for 24 hours. Porcine Pepsin A (20 U/g; Worthington Biochemical Corporation, 
Lakewood, NJ) was added to the mixture. The mixture was stirred at 4 ᵒC for 48 hours. The 
insoluble fraction was again removed by filtration using cheesecloth and the filtrate was 
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subjected to precipitation by adding 2.6 M NaCl and 0.05 M tris (hydroxymethyl)- 
aminomethane. 5 M NaOH in small increasing volumes (while continuously checking for pH, 
using pH strips) was then added to get the filtrate to a pH of 7.0. The precipitate was then 
ultracentrifuged at 20,000 x g/198,000 rpm for 1 hour. The resulting pellet was re-suspended in 
1 ml of 0.5 M acetic acid, by stirring on a shaker until the pellet dissolved70,71. Since the pellet 
did not dissolve completely after 48 hours, gentle mechanical disruption, using a glass rod, was 
used to facilitate dissolution. 
3.3.4 Separation of Col 1 and Col 3 
Differential salt precipitation was performed using 1.5 M NaCl for separating Col 3 from the 
collagen fractions obtained using the above pepsin digest extraction72. The pH was then 
neutralized to 7.0 using 5 M NaOH and ultracentrifugation was performed                           
(20,000 x g/ 198,000 rpm for 1 hour). The pellet was re-suspended in 0.5 M glacial acetic acid 
(100 µl). The supernatant from this was subjected further to differential salt separation, using 
2.5 M NaCl, to separate out Col 1. The pellet was re-suspended in 0.5 M glacial acetic acid         
(50 µl). Western blot analysis was used to identify Col 1 and Col 3 from the isolated fractions72. 
Examples of dilutions and calculations used: 
 To obtain 2.6 M NaCl: 
Molecular weight of NaCl=58.44  
2.6 M of NaCl=58.44*2.6=152 mg of NaCl per ml of solution. 
 To obtain 0.05 M of tris 
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Molecular weight of tris=121.14 
50mM of tris base=121.14 mg/ml*0.05=6.057 mg of tris base per ml of solution. 
 To obtain 0.5 M glacial acetic acid: 
Molecular weight of glacial acetic acid: 60.05 Molarity=17.4 
To make 50 ml of 0.5M of glacial acetic acid= 17.4/0.5= 34.8 X dilution= 50 ml/34.8=1.44 ml of 
acetic acid in 48.56 ml distilled water (QPod®, Millipore, Billerica, MA) 
 Calculations for Ultracentrifuge 
We used specially designed open-top tubes for ultracentrifuge (Beckman Coulter, Fullerton, 
CA). Manufacturer instruction specified that each tube should be filled with 32-37 ml of 
solution. Therefore, all solutions were brought to a final volume of 32-37 ml, before 
ultracentrifuging.     
3.4 Western Blot Analysis 
Western blot analysis was performed to determine efficiency of the Col 1 and Col 3 separation 
protocol, using standardized protocols73, with additional optimizations developed by our lab.  
BCA Assay (BCA Protein Assay Kit, Pierce™, Rockford, IL), was performed to determine protein 
concentration in our Col 1 and Col 3 separated samples. This was followed by dilution of the 
proteins using 2-Mercaptoethanol (Bio-Rad, Hercules, CA) and dye (NuPAGE®, LDS sample 
buffer 4X, Invitrogen, Carlsbad, CA) followed by heating in a heating block (Incublock™, Denville 
Scientific Inc., Holliston, MA) (95 ᵒC for 5 minutes). Equivalent amounts of protein (10 ng/µl) 
were loaded into the lanes of a 4-12 % Bis-Tris gradient gel (NuPAGE™ Novex™, ThermoFisher 
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Scientific) along with a molecular weight marker (Precision Plus Protein™, dual color standards, 
Biorad, Hercules, California). These proteins were then separated by molecular weight by 
electrophoresis (approximately 1 hour at 50-150 V) and then transferred to a PVDF membrane 
(Polyvinylidene fluoride; Immobilon-P, Millipore Corporation, Billerica, MA). To accomplish the 
transfer, a stack was prepared, placing the membrane and gel facing each other, in between 
filter paper, sponges and supports, with one end connected to the positive of the voltage 
source and the other end to the negative. This was run for 75 minutes at 75 V. After the 
transfer was complete, the membrane was blocked at room temperature using 5 % (w/v) de-fat 
milk in PBST (0.1 % Tween 20 in 1X PBS) (to prevent non-specific binding of antibodies in 
subsequent steps), with 3X changes. Primary antibody was prepared in the 5 % (w/v) de-fat dry 
milk and the membrane was incubated overnight, with gentle shaking on a rocker (4 °C). The 
membrane was then washed three times (5 minutes per wash) in 5 % (w/v) de-fat milk in PBST. 
The membrane was then incubated with the required dilution of conjugated secondary 
antibody in 5 % (w/v) non-fat dry milk at room temperature for 1 hour with gentle shaking on a 
rocker, in a dark room. Prior to imaging, the membrane was again washed two times each in     
5 % (w/v) milk, PBST and PBS for 10 mins each to remove excess antibody not bound to the 
membrane. The membranes were finally imaged by an enhanced chemiluminescence (ECL) 
system (SuperSignal® WestPico Chemiluminescent substrate, Thermo Scientific, Rockford, IL), 
according to manufacturer’s recommendations. The membrane was incubated using the 
working ECL solution for 1 minute at room temperature. The blot was then removed from the 
working solution and was placed in a film cassette between protective plastic sheets. Hyblot CL 
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autoradiographic film was placed on top of the membrane and exposure time was optimized 
for each experiment.  
For Col 1 detection Goat anti-type l collagen (Southern Biotech, Birgimham, Alabama) was used 
as a primary antibody (1:500 dilution) and Peroxidase conjugated donkey anti goat IgG (H+L) 
(Jackson Immuno Research, West grove, PA) was used as the secondary antibody (1: 10,000 
dilution). The Col 3 antibody (Anti-Collagen III antibody, ab7778, Abcam, Cambridge, MA), 
which was used in other papers for western blots74-76, was found to exhibit cross-reactivity with 
Col 1. 74,75,76 
3.5 PCL Electrospinning 
 
PCL electrospinning was performed using a custom-built apparatus consisting of a high-voltage 
source, rotating mandrel, fanner and syringe pump. 
 
Fig.3.5. Shows the custom-built electrospinning setup used for spinning aligned and unaligned 
PCL scaffolds. 
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3.5.1 Preparation of the PCL Solution 
PCL (14.3 % (w/v), 80 kDa; Sigma, St. Louis, MO) was dissolved in equal parts of 
Dimethylformamide and Tetrahydrofuran (DMF: THF; Sigma, St. Louis, MO). For the purpose of 
our project, we dissolved 4 g of PCL in 14 ml of THF and 14 ml of DMF (28 ml solution in total) at 
40 ᵒC for approximately 24 hours. 
3.5.2 Preparation of unaligned PCL scaffolds 
PCL solution (15 ml) was loaded into a 20 ml syringe (BD ™, Franklin Lakes, NJ) and ejected 
through a 12” long 18G stainless steel needle (which acted as a charged spinneret, controlled 
by a fanner), fitted with a 5 cm flexible silicone tube, using a syringe pump (KDS100, KD 
Scientific, Holliston, MA) at 2.5 ml/hr. The distance between the tip of the needle to the 
mandrel was about 13 cm. A high voltage source (ES30N-5V, Gamma High Voltage Research, 
Ormond Beach, FL) was used to introduce a potential difference of +13 kV between the 
spinneret and the metal mandrel (grounded). The mandrel was kept static (linear surface 
velocity of 0 m/s). Aluminum plates, charged to 10 kV were placed on either side of the 
mandrel, to improve the collection focus of the fibers on the mandrel. The mandrel was coated 
with silicone spray to facilitate easy removal of the mesh. Room humidity was maintained at 
approximately 30 % and temperature was maintained between 22-27 ˚C. 
3.5.3 Preparation of aligned PCL scaffolds 
The set up for the aligned PCL was similar to the one used for unaligned PCL except that the 
mandrel linear surface velocity was increased to 10 m/s. 
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3.5.4 Preparation of PCL and Col 1 composites 
Col 1 from rat tail (Sigma Aldrich, St. Louis, MO) was dissolved in HFP (1,1,1,3,3,3-Hexafluoro-2-
propanol; Sigma-Aldrich, St. Louis, MO; 8 % (w/v)) while being stirred continuously for 24 hours. 
The distance between mandrel and syringe was adjusted between 12-12.5 cm and the solution 
ejection rate was set to 0.02 ml/hr. The solution was directed onto a stationary copper plate, 
connected to a high voltage source (10 kV). 
3.6.1 Dilution of Col 1 and Col 3 
Recombinant Col 1 (1 µg/cm2, Bornstein & Traub Type l, expressed in nicotiana; Sigma Aldrich, 
St. Louis, MO) and recombinant Col 3 (1 µg/cm2, RhC 3-012 collagen type lll, Fibrogen, San 
Francisco, CA) were diluted in 10 mM glacial acetic acid.  
3.6.2 Collagen coating of electrospun scaffolds and culture surfaces 
Collagen coating of surfaces for cell culture, either cover slips (12-545-82, Fisherbrand, 
Waltham, MA) or PCL (aligned and unaligned), was performed in 24-well plates using 
recombinant Col 1 or Col 3. 
3.6.3 Coating conditions 
Glass cover slips (1.13 cm2 surface area) were coated with either recombinant Col 1 (1 µg/cm2) 
or Col 3 (1 µg/cm2). After 1-2 hours, the collagen solutions were aspirated and the cover slips 
were allowed to completely dry for 5-10 minutes and transferred to new wells, before 
proceeding with cell seeding. This was done to ensure that the cells preferentially attached to 
the coated coverslip or PCL, instead of the collagen-coated tissue culture well.  
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PCL scaffolds were first sterilized with 100 % ethanol (Decon Labs Inc., King of Prussia, PA) for    
20 minutes and then rehydrated using decreasing concentrations (80 %, 70 %, 50 %, 30 %, 10 %) 
of ethanol for 20 minutes each, followed by changes of PBS (3 X). The PCL scaffolds were then 
cut into approximately 1.0 cm2 squares, using a surgical blade. Extreme care was taken while 
doing this, to reduce the risk of tears or holes in the mesh. The PCL squares were then placed 
into the wells of a 24 well plate. After one more wash in PBS, equal amounts of recombinant 
Col 1 (1 µg/cm2) or Col 3 (1 µg/cm2) was added to each well. The scaffolds were then left to air 
dry overnight in the laminar hood. The following morning the collagen-coated scaffolds were 
carefully removed from their wells using forceps and placed into new wells prior to cell seeding, 
as described above.  
3.7 Cryopreservation, Cell culture, Trypsinization and Cell counting 
All cell lines were cryopreserved using freezing media containing FBS (95 %) and DMSO (5 %) in 
an -80 ˚C freezer or liquid nitrogen.  
Prior to cell culturing, all cell lines were thawed in a 37 ˚C water bath (Precision Scientific, 
Chicago, IL). All cell lines were cultured with DMEM containing D-glucose (4.5 g/l) and sodium 
pyruvate (110 mg/l), supplemented with 10 % FBS and 1 % Pen-Strep (10,000 U/ml penicillin 
and 10,000 µg/ml streptomycin; Biowhittaker®, Lonza, Walkersville, MD), unless otherwise 
specified. Following thawing, cells were plated at a concentration of 1x106 per 100 mm cell 
culture dish and allowed to grow for 24 hours in an incubator (37 ᵒC, 5 % CO2; Forma™ Series ll 
Water Jacketed CO2 incubator, Thermo Scientific) before seeding onto cover slips or PCL 
scaffolds. 
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The following day, cells were trypsinized using 0.25 % Trypsin-EDTA solution (1X, Gibco™, 
ThermoFisher Scientific, Green Island, NY) (37 ᵒC, 5% CO2) until the cells dislodged from the 
plate. For the MDA-MB-231 cell line the time for trypsinization was ~4-5 minutes and for the 
A549 cell line, the time was ~6-7 minutes. The trypsinized cells (3 ml) were then transferred to a 
15 ml tube and 7 ml of DMEM (10 % FBS, 1 % Pen-Strep) was then added to the tube to 
inactivate the trypsin. A cellular pellet was obtained by centrifugation (178 x g/1000 rpm for      
5 minutes) and re-suspended in 10 ml of DMEM (10 % FBS, 1 % Pen-Strep). 
Cells were counted using a standard Hemocytometer (Hausser Scientific, Horsham, PA) and 
diluted to the required concentration. For the purpose of counting, the following method was 
used: 
 
 
Fig.3.4. Hemocytometer 
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10 µl of the cells, were loaded onto the Hemocytometer. Hemocytometers are divided into 9 
large squares (figure above). Cells in all of 9 squares were counted. For ex: If we counted that 
there were 90 cells in all 9 squares combined. 
90/9 = 10x104 cells per ml of media 
Let the required cell concentration be 4 x104 cells/ ml. 
10x104 cells/ ml / 4 x104 cells/ ml = 2.5 X dilution 
Let us assume we need to make 10 ml of cells totally. 
10 ml/ 2.5 X Dilution factor = 4 of ml of cells from original tube. 
4 ml of cells from original tube + 6 ml of fresh DMEM (10 % FBA, 1 % Pen-Strep) is added to the 
new tube. 
3.8 Induction of apoptosis using high temperature and starvation 
Serum starvation (exposure to media without serum) and high temperature were investigated 
as methods for inducing apoptosis in the murine (4T1) and human (MDA-MB-231) breast cancer 
cell lines. For apoptosis assays, cells were plated in 24 well plates at a density of approximately 
17.7 X 103 cells/cm2. 
Serum-starvation: 
Cells were cultured under conditions of serum-starvation (DMEM with 1% Pen-Strep) for           
48 hours in a CO2 incubator (5 %, 37 ˚C). Cells cultured under the same conditions except for 
DMEM with 1 % Pen-Strep and 10 % FBS served as controls.  
Combination of high temperature and serum-starvation: 
47 
 
Following serum-starvation for 48 hours, cells were incubated for 1 hour and 2 hours at 42 ˚C in 
a CO2 incubator (5%). Cells cultured in DMEM supplemented with 1 % Pen-Strep and 10 % FBS 
(5 % CO2, 37 ˚C) served as controls 
As both these methods were inefficient in inducing consistently reproducible apoptosis, 
chemotherapeutic reagents were explored as an inducer of apoptosis. 
3.9 Stimulation of apoptosis using Staurosporine 
Staurosporine (MW=466.53; Apex Bio, Boston, MA) was used as an inducer of apoptosis in our 
experiments. Staurosporine was diluted using DMSO (Fisher Bioregents®, Fair Lawn, NJ) and 
stored at -20 ᵒC. During the experiment, it was quickly thawed using a 37 ᵒC water bath. For the 
purpose of our project, optimal induction of apoptosis yielded quantifiable and reproducible 
induction of apoptosis in the cell lines while preserving sufficient cells per field of view                    
(≥ 20 cells/frame) for reliable quantitation. Optimal staurosporine concentration and exposure 
were determined to be 1 µM for 24 hours.  
Cells were seeded onto tissue culture wells (surface area of individual wells in the 24 well plate 
= 1.9 cm2) containing Col 1 or Col 3-coated cover slips or PCL scaffolds in 1.0 ml of DMEM 
supplemented with 10 % FBS, 1 % Pen-Strep. The cells were allowed to adhere to the surface of 
the cover slips or the PCL for 2 days (37 ᵒC, 5 % CO2). After two days, 1 µM of staurosporine was 
added carefully to each well.  After an additional 24-hour incubation, cells were fixed using PFA 
(Paraformaldehyde; Electron Microscopy Sciences, Hatfield, PA; 4 % in PBS) and analysis by 
immunofluorescence was performed (described in detail in Sec 3.10).  
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3.10 Detection of apoptosis by immunofluorescence for activated caspase 3 
For activated caspase 3 immunofluorescence, cells seeded on collagen-coated cover slips and 
PCL (aligned and unaligned) constructs were carefully washed with 1 X PBS prior to fixation 
using 400 ml/well of PFA for 15 minutes. During incubation, the samples were protected from 
light to prevent photobleaching. Cells were permeabilized using 400 ml/well of Triton-X (0.5 % 
in PBS) (Roche, Indianapolis, IN) for 15 minutes. This was followed by blocking using 400 
ml/well of Bovine Albumin Serum (5 % in PBS) (Sigma Aldrich, St. Louis, MO) for 15-20 minutes. 
Cells were then incubated with activated Caspase-3 (Asp175) (5A1E) Rabbit mAb #9664 (Cell 
Signaling Technology®, Danvers, MA) primary antibody (1:400 dilution) for 1 hour (37˚C, 5% 
CO2). This was followed by three washes in 1 X PBS, with one of the washes with gentle 
agitation on a rocker. The cells were subsequently incubated in Goat-anti rabbit IgG (H+L) 
secondary antibody, Alexa Fluor® 594 conjugate (1:500 dilution) (ThermoFisher Scientific, 
Rockford, Illinois) for 30 minutes (37 ˚C, 5 % CO2). This was followed by 3 washes in 1X PBS, with 
one of the washes performed with gentle shaking on a rocker. The cover slips and PCL were 
then mounted on glass slides using Vectashield mounting media containing DAPI                             
(4′,6-diamidino-2-phenylindole; Vectorlabs Inc., Burlingame, CA). The cells were then imaged 
using Olympus BX51 (Olympus®, Melville, NY) fluorescence scope. Signals from the DAPI filter 
(nuclei) were assigned blue and those from the TRITC filter (active caspase 3) were assigned 
red. Percentage of cells undergoing apoptosis were quantified using ImageJ software, as 
described above. 
Antibody dilution examples: 
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If there were 5 wells to be stained, and 400 ml of primary and secondary antibody is used per 
well, then 2000 ml of primary and secondary antibody are required respectively. 
For 1:400 dilution of primary antibody: 2000/400= 5 µl of antibody is diluted in 2 ml of PBS.  
Similarly, for 1:500 dilution of secondary antibody: 2000/500= 4 µl of antibody is diluted in 2 ml 
of PBS. 
3.11 SEM imaging 
The SEM imaging protocol consisted of the following steps: sample fixing, sample dehydration, 
chemical drying, sputter coating with metal alloy and imaging. The samples (cover slips or PCL 
coated with Col 1 and Col 3, with or without cells seeded onto them) were carefully washed 
with 1 ml of 1 X PBS per well. The samples were then fixed using 0.4 ml of PFA (4 % in PBS) per 
well, for 15 minutes. The samples were washed again using 1 X PBS and then were subjected to 
dehydration using 1 ml of increasing concentrations of ethanol (1 X change of 30 %, 50 %, 70 %, 
80 %, 90 %, 95 % and 3 X changes of 100 %) for 20 minutes each. The samples were chemically 
dried using Hexamethyldisilazane (HMDS) the following day. Specifically, 1 ml of HMDS 
(Electron Microscopy Sciences, Hatfield, PA) was added to each well (containing the sample) for 
20 minutes (2 X changes) and left to air dry in a final change of HMDS overnight. The samples 
were then mounted on SEM specific aluminum stubs (12.7 mm diameter; Electron Microscopy 
Sciences, Hatfield, PA) and were taped to the stubs using double-sided carbon tape (8 mm x 20 
m on 76 mm plastic core; SPI® supplies, Westchester, PA). The stubs (with the samples 
attached) were then taken for sputter coating with AU-Pd alloy. A Polaron sputter coater was 
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used for the purpose. The prepared samples were then taken for imaging using the              
Quanta FEI 250 SEM Imager (FEI®, Burlington, MA). 
3.12 Data Analysis 
Data in figures are expressed as means ± standard error of the mean (SEM), unless otherwise 
stated. For all experiments (in vitro), normality of data was confirmed by K-S test using Minitab 
software, followed by unpaired student’s t-tests. The tests were used to determine the 
significance of the difference between apoptosis percentages and axis ratios between groups. 
Study groups were compared utilizing GraphPad Prism 7 statistical software. p-values of less 
than 0.05 were considered significant. 
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CHAPTER 4: RESULTS, DISCUSSIONS AND FUTURE WORK 
4.1 Western blot analysis of Col 1 and Col 3 separated fractions 
Western blot analysis was performed to examine Col 1 and Col 3 expression, after the 
separation protocol (detailed in Chapter 3) was applied to the isolated pepsin-digested 
collagen. For Col 1 detection, Goat anti-type l collagen (Southern Biotech; 1:500 dilution) was 
used as a primary antibody and Peroxidase conjugated donkey anti goat IgG (H+L) (Jackson 
Immuno Research; 1: 10,000 dilution) was used as the secondary antibody.  
                  
Fig.4.1. Western blot to detect Col 1 in collagen samples (Col 1 and Col 3-separated; 30 second 
exposure) 
The analysis showed Col 1 bands in rat tail collagen type 1, Col 3 -/- and wild type fibroblasts 
(embryonic dermal), as expected. An increased expression of Col 1 was observed in fibroblasts 
derived from Col 3 -/- mice compared to fibroblasts derived from wild-type mice, and is 
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consistent with Col 3 deficiency inducing myofibroblast activation and subsequent collagen 
deposition. As expected, no Col 1 was seen in recombinant Col 3. Therefore, we were able to 
confirm the specificity of our antibody for Col 1 detection. However, Col 1 expression was 
observed in both of our separated fractions (Col 3 and Col 1), suggesting that the protocol had 
been ineffective in separating Col 3 and Col 1. Thus, we decided to continue further 
experimentation with commercially sourced recombinant Col 3 and Col 1.  
4.2 Effect of Col 3-coated cover slips on the apoptosis of MDA-MB-231 cells, using 
Staurosporine as an apoptotic stimulus: Preliminary apoptosis studies 
As discussed in the first two chapters, Col 3 has been previously shown to induce murine breast 
cancer cell apoptosis. To test if Col 3-coated substrates induce apoptosis of human breast 
cancer cells, MDA-MB-231 cells (4 x 104 cells/well; 48 hours) were seeded onto Col 3 or Col 1 
(control)-coated cover slips with 1 µM Staurosporine exposure (24 hours). The cells were then 
fixed and immunofluorescence was performed to detect active Caspase 3. Quantification of 
apoptosis was performed as described above.  
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Fig.4.2a. Immunofluorescence images showing MDA-MB-231 cells seeded onto Col 3 and Col 1-
coated cover slips. DAPI binds AT-rich regions of DNA and therefore stains the nucleus of the 
cells (blue). Activated Caspase 3 (TRITC) immunoreactivity demonstrates cells undergoing 
apoptosis (red). Merged images demonstrate the cells which are positive (nucleus of the cells 
merging with red stain) or negative for caspase 3 activity (only blue nuclear stain). 
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Fig.4.2b. Graph indicating the percentage of apoptotic MDA-MB-231 (active caspase 3 positive) 
cells when seeded onto Col 1 and Col 3 coated cover slips, using Staurosporine as an apoptotic 
stimulus. Student t-test (n=3) showed significance (p=0.0184). 
Shown above is a graph showing n=3 independent experiments (each experiment with triplicate 
images per condition). Col 3 substratum was effective in promoting apoptosis in MDA-MB-231 
cells compared to a Col 1 substratum, similar to what had been observed in murine 4T1 breast 
cancer cells. 
4.3 Effect of Col 3 coating of aligned PCL on the apoptosis of MDA-MB-231 cells, using 
Staurosporine as an apoptotic stimulus 
With favorable preliminary test results, we investigated the hypothesis that Col 3-coated 
fibrous biomaterials can promote apoptosis of MDA-MB-231 cells compared to Col 1-coated 
biomaterials. We seeded 1 cm2 Col 1- and Col 3- coated aligned PCL scaffolds with 4 x 104                
MDA-MB-231 cells (48 hours) and then exposed these cells to 1 µM Staurosporine (24 hours). 
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Immunofluorescence was performed to detect active caspase 3 and the percentage of 
apoptosis was quantified. 
 
Fig.4.3a. Immunofluorescence images showing MDA-MB-231 cells coated onto Col 3 and             
Col 1-coated aligned PCL scaffolds. DAPI (blue), activated caspase 3 (TRITC; red) and merged 
images demonstrate the cells which are positive or negative for caspase 3 activity (nucleus of 
the cells merging with red stain vs. those with only blue nuclear stain, respectively). 
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Fig.4.3b. MDA-MB-231 breast cancer cell active caspase 3 immunoreactivity of cells seeded onto 
Collagen-coated aligned PCL scaffolds (student t-test (n=5), p=0.0067). 
Shown above is a graph showing n=3 independent experiments (each experiment with triplicate 
images per condition).  All experiments showed a consistent trend and data analysis confirmed 
the ability of Col 3 coated aligned biomaterials to promote human breast cancer cell apoptosis.   
4.4 Aligned and unaligned PCL scaffolds: Fiber orientation analysis 
To investigate our secondary objective, we determined if the fiber orientation of the scaffolds 
would affect morphology and apoptosis in breast cancer cells. Aligned and unaligned PCL 
scaffolds were produced in the Mauck lab as previously described (detailed in Sections 3.5.2 
and 3.5.3). To confirm fiber orientation in both scaffold types, SEM imaging was performed on 
samples and fiber orientation was analyzed using two methods: 1) The first method used an 
ImageJ plugin called OrientationJ, which is specifically designed to measure fiber orientation in 
SEM images. 2)The second method used the concept of circular variance, which measures a set 
of dehydral angles, where the values range from 0 to 1. A value closer to 1 signifies a more 
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unalgined orientation77,78. Using OrientationJ had the advantage of analyzing almost all the 
fibers in the image, automatically using the software, therefore avoiding any kind of bias. Using 
circular variance provided us with a more direct method to analyze fiber orientation, but the 
method required selection of a limited number of fibers per image. This method carries the risk 
of introducing bias through the selection of fibers.  
 
Fig.4.4a. Top panel: Uncoated unaligned PCL fibrous mesh (500X magnification) and the 
corresponding histogram for fiber orientation (top right). Bottom panel: Uncoated aligned PCL 
fibrous mesh (500X magnification) and the corresponding histogram for fiber orientation (top 
right).  
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The histograms obtained confirmed the alignment of our fibrous scaffolds. Aligned PCL fibers 
showed a preference for orientation in one principal direction (peak of the histogram occurred 
at one principal orientation angle). Unaligned PCL fibers showed no preferential orientation in 
direction (almost flattened peaks were observed in the histogram at different orientation 
angles, showing that the fibers were oriented at different angles).  
For quantifying circular variance, the angles of fibers in three SEM images of uncoated aligned 
and unaligned PCL scaffolds were measured using ImageJ and the angles were applied to the 
circular variance formula: 
𝑉𝑎𝑟(𝜃) = 1 − 𝑅𝛼𝑣 
𝑅𝛼𝑣 = 𝑅/𝑛, where n give the number of members in the list. Where R is given by, 
𝑅2 = (∑ cos 𝜃
𝑛
𝑖=1
)
2
+  (∑ sin 𝜃
𝑛
𝑖=1
)
2
 
The formula was simulated using a program in MATLAB and was coded with the help of Qing Li 
from the Han Lab at Drexel (program detailed in the appendix). 
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Fig.4.4b. The graph represents the circular variance values (Mean +/- SEM) for three scanning-
electron- images of uncoated unaligned and aligned PCL (n=3), with circular variance analyzed 
for approximately 60-100 fiber per image. Student t-test was performed and the results were 
found to be significant (p= 0.0064). 
As expected, uncoated unaligned scaffolds showed circular variance values closer to 1, while 
aligned scaffolds showed values closer to 0. 
4.5 Col 3-coated aligned and unaligned PCL scaffolds: Fiber orientation analysis 
To determine if Col 3 coating of scaffolds had any effect on fiber alignment, fiber orientation of 
the Col 3-coated aligned and unaligned PCL fibers was analyzed. We SEM imaged the samples 
and performed orientation analysis on the images using ImageJ. 
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Fig.4.5a. Top panel:  Col 3-coated unaligned PCL fibrous mesh (500 X magnification) and the 
corresponding histogram for fiber orientation (top right). Bottom panel: Col 3-coated aligned 
PCL fibrous mesh (500X magnification) and the corresponding histogram for fiber orientation 
(bottom right).  
Similar to the histograms obtained for fiber orientation of uncoated aligned and unaligned PCL 
scaffolds (Fig. 4.4), the histogram obtained for Col 3-coated aligned PCL fiber scaffolds revealed 
fiber orientation in one principal direction (peak of the histogram occurred at one principal 
orientation angle). Col 3-coated unaligned PCL fibers showed no preferential orientation in 
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direction (decreases in peak amplitudes were observed in the histogram at different orientation 
angles, showing that the fibers were oriented at different angles).  
Similar to the circular variance analysis described in the previous section, the circular variance 
of Col 3-coated aligned and unaligned scaffolds was quantified. 
 
Fig.4.5b. The graph represents the circular variance values (Mean +/- SEM) for three scanning- 
electron images of Col 3 coated unaligned and aligned PCL (n=3), with circular variance analyzed 
for approximately 60-100 fibers per image. Student t-test was performed and the results were 
found to be significant (p=0.0016). 
As expected, Col 3-coated unaligned scaffolds showed circular variance vales closer to 1, while 
Col 3-coated aligned scaffolds showed values closer to 0, representing expected fiber 
orientation in both. 
This confirmed that Col 3 coating protocol did not significantly alter the overall alignment of the 
PCL fibers in the scaffold 
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4.6 Cell elongation analysis: Uncoated and Col 3 coated aligned and unaligned PCL scaffolds 
As discussed in Sec. 2.5.3. fiber orientation in electrospun fibrous scaffolds has been shown to 
effect cell morphology. Studies suggest that aligned scaffolds promote elongation of breast 
cancer cells, indicative of an aggressive cancer cell phenotype79. By comparison, unaligned 
scaffolds appear to suppress cancer cell elongation and promote a more rounded morphology. 
To determine if our uncoated and Col 3-coated unaligned PCL scaffolds would limit elongation 
of cells, MDA-MB-231 cells (4 x 104 cells/well) were seeded onto control and Col 3-coated 
aligned and unaligned scaffolds and cultured for 48 hours. SEM images were taken and 
elongation was analyzed as described above. Axis ratios of cells on uncoated, unaligned PCL 
compared to cells on aligned PCL were plotted.  This was also performed for cells cultured on 
Col 3-coated scaffolds. Data was analyzed using an unpaired student t-test to check for 
significance, on GraphPad Prism 7 software. Three samples were analyzed per condition, with 
50-100 randomly picked cells analyzed per sample. 
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Fig.4.6a. MDA-MB-231 cells (4 x 104 cells/well) were seeded onto uncoated aligned and 
unaligned PCL scaffolds for 48 hours. A-C) Cells seeded onto uncoated unaligned PCL scaffolds 
(200 X, 500 X, 2000 X magnification, respectively) exhibit a rounded morphology. Cells in C show 
that a stellar-like shape is associated with attachment to multiple fibers. D-F) Cells seeded onto 
uncoated aligned PCL scaffolds (200 X, 500 X, 1000 X magnification) exhibit a more spindle-
shaped morphology compared to those on unaligned scaffolds. Cells in F show these elongated 
cells attaching along the fiber axis. 
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Fig.4.6b. Analysis of the effect of fiber orientation on MDA-MB-231 cell elongation. Cells were 
seeded onto uncoated aligned and unaligned PCL scaffolds and axis ratios determined. Three 
samples were analyzed for each condition (50-100 cells analyzed per sample). Aligned scaffolds 
promoted elongation of cultured breast cancer cells compared to unaligned scaffolds (p=0.0099; 
student’s t-test). 
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Fig.4.6c. MDA-MB-231 cells (4 x 104 cells/well) were seeded onto Col 3 coated aligned and 
unaligned PCL scaffolds for 48 hours. A, B, C) Show cells seeded onto Col 3-coated unaligned PCL 
scaffolds (200 X, 1000 X, 2000 X magnification), with more number of cells showing a stellar like 
morphology rather than spindle shaped morphology. Cells in C also show a tendency to attach 
to multiple fibers to attain the stellar like shape. D, E, F) Show cells seeded onto Col 3-coated 
aligned PCL scaffolds (200 X, 500 X, 2500 X magnification), with more number of cells showing a 
spindle shaped morphology, as opposed to a stellar like morphology. Cells in F show a 
preference to grow along the fiber axis, to attain the said morphology. 
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Fig.4.6d. Graph showing the axis ratio MDA-MB-231 cells seeded onto Col 3 coated aligned and 
unaligned PCL scaffolds. Three samples were analyzed for each condition, with 50-100 cells 
analyzed for each sample (n=3). Aligned scaffolds promoted elongation of cultured breast 
cancer cells compared to unaligned scaffolds. Student t-test showed significance (p=0.0084). 
Axis ratio analysis of MDA-MB-231 cells seeded onto uncoated aligned and unaligned PCL 
scaffolds (Fig 4.6b) and Col 3-coated aligned and unaligned PCL scaffolds (Fig 4.6d) confirms 
that aligned PCL scaffolds (both uncoated and Col 3 coated) promote an elongated cell 
morphology as opposed to cells on unaligned PCL scaffolds (both uncoated and Col 3 coated). 
Unaligned scaffolds (both coated and uncoated) promote less elongated cell morphology (more 
rounded, stellar-like morphology). The ability of unaligned PCL to limit the elongation of cancer 
cells is dependent on fiber orientation itself and appears not to be affected by the presence of 
Col 3. However, based on this data, we hypothesized that Col 3-coated unaligned PCL scaffolds 
would promote apoptosis in cancer cells seeded onto them, as opposed to those seeded onto 
Col 3-coated aligned PCL due to the relationship between an elongated phenotype and 
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resistance to apoptosis (discussed in sec 2.5.3). Therefore, by limiting such aggressive 
phenotypes, unaligned fibers could potentiate Col 3-induced apoptosis in MDA-MB-231 cells. 
To test this hypothesis, we examined if Col 3-coated unaligned fibers would promote 
significantly higher amount of apoptosis in MDA-MB-231 cells than Col 3-coated aligned fibers. 
4.7 Effect of fiber alignment of Col 3 coated PCL scaffolds on the apoptosis of MDA-MB-231 
cells 
Finally, to determine if fiber orientation modulates apoptosis of cells seeded onto Col 3 coated 
biomaterials, we seeded Col 3-coated aligned and unaligned PCL with MDA-MB-231 cells          
(8 x 104 cells/well, 48hours) and subsequent exposure of cells to 1 µM Staurosporine for            
24 hours. 
 
Fig.4.7a. Immunofluorescence images showing MDA-MB-231 cells seeded onto Col 3-coated 
aligned and unaligned PCL scaffolds. DAPI (blue), activated caspase 3 (TRITC; red) and merged 
68 
 
images demonstrate the cells which are positive or negative for caspase 3 activity (nucleus of 
the cells merging with red stain vs. those with only blue nuclear stain, respectively). 
 
  
Fig.4.7b. Percentage of apoptotic MDA-MB-231 cells (active caspase 3 positive) seeded onto Col 
3-coated PCL scaffolds. Col 3-coated unaligned PCL showed a higher apoptosis percentage of 
MDA-MB-231 cells (n=3) with triplicate samples analyzed in each independent experiment; 
(p=0.0066, Student t-test). 
Our data supports that unaligned (Col 3-coated) scaffolds promote a significantly higher level of 
MDA-MB-231 cell apoptosis than aligned scaffolds (p=0.0066). In the future, we will compare 
apoptosis in Col 3- and Col 1-coated unaligned scaffolds. Based on our results showing 
increased apoptosis of MDA-MB-231 cells on Col 3- coated aligned scaffolds versus Col 1-coated 
aligned scaffolds, we anticipate that Col 3-coated unaligned scaffolds will be superior in 
inducing apoptosis compared to Col 1-coated unaligned scaffolds (as show in Sec 4.3). 
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4.8 Effect of Col 3 coated cover slips on the apoptosis of A549 cells, using Staurosporine as an 
apoptotic stimulus 
As our final objective, we determined if Col 3-coated substrates promote apoptosis of other 
cancer cells lines. Human lung cancer A549 cells (4 x 104 cells/well) were seeded onto Col 3-
coated cover slips (48 hours) and then exposed to 1 µM Staurosporine (24 hours). Experimental 
setup and data analysis was similar to that detailed in Sec 4.2. 
 
Fig.4.8a. Immunofluorescence images showing A549 cells coated onto Col 3 and Col 1 cover 
slips. DAPI (blue), activated caspase 3 (TRITC; red) and merged images demonstrate the cells 
which are positive or negative for caspase 3 activity. 
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Fig.4.8b. Graph indicating the apoptosis percentage (active caspase 3 positive) of A549 cells 
seeded onto Col 3 coated cover slips. Col 1 coated cover slips were used as a control. Student t-
test (n=6), with triplicate samples analyzed in each independent experiment, showed 
significance (p=0.0305). 
Similar to our findings with using the human breast cancer cell line MDA-MB-231, Col 3 
increased apoptosis in the human lung cancer cell line (A549) compared to Col 1 (p=0.0392).   
4.9 Discussion 
Col 3 plays a critical role in modulating regenerative and tumor microenvironments. The fact 
that many of the same mechanisms which regulate wound healing also promote tumor 
progression, is recognized by the WHFC triad. A greater understanding of the role for Col 3 in 
the WHFC triad has motivated the Volk lab to apply this knowledge to engineer optimal healing 
and anti-tumor environments in hope of improving breast cancer patient clinical outcomes. 
Based upon their findings on the mechanisms by which Col 3 regulates cell behavior, we 
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hypothesize that the use of Col 3-coated biomaterials may provide a safe, non-toxic and 
effective method to control breast cancer recurrence.  
The in vitro data presented in this chapter, presents us with the following conclusions: 
i) Col 3-coated substrates (cover slips) promote apoptosis of breast cancer cells         
(MDA-MB-231) seeded onto them compared to Col 1 controls, providing proof-of-
concept that Col 3 may eliminate residual microscopic disease if incorporated into 
biomaterials for oncologic reconstruction. 
ii) Col 3-coated electrospun fibrous scaffolds (PCL) promote a significantly higher amount 
of breast cancer cell (MDA-MB-231) cell apoptosis compared to Col 1-coated scaffolds. 
Therefore, suggesting the potential of these biomaterials for in vivo applications to 
eliminate/reduce tumor burden and also prevent local recurrence and breast cancer 
metastasis. Further development of such biomaterials might prove to be an 
improvement over Col 1 biomaterials, which are used extensively in medicine for 
oncologic reconstruction in breast cancer excisional sites. Previous data by the Volk lab 
on the effect of Col 3 on wound healing, also suggests that Col 3-coated scaffolds will 
promote wound healing in the excisional sites. This however requires further research. 
iii) Fiber orientation of the electrospun PCL scaffolds have the ability to affect cancer cell 
morphology, with aligned (control and Col 3-coated) scaffolds promoting cancer cell 
elongation compared to those on unaligned scaffolds. Since cell morphology is known to 
regulate apoptosis (as explained in the first chapter), we hypothesized that unaligned 
fibers would be more potent in inducing apoptosis of breast cancer cells compared to 
aligned fibers. Our data support this hypothesis.  Specifically, Col 3-coated unaligned PCL 
72 
 
promoted significantly higher apoptosis than Col 3 coated aligned PCL (p=0.0066). This 
suggests Col 3-coated unaligned scaffolds have the optimal characteristics of those 
tested in inducing breast cancer cell apoptosis.  
iv) Preliminary data also suggest that Col 3-based therapies may be effective in controlling 
over cancer types, such as lung cancer, as our data showed a Col 3-coated substratum 
increased apoptosis in in human lung carcinoma (A549) cells compared to Col 1. Our      
in vitro tests, therefore, provide definite data to motivate further research on Col 3 
biomaterials, to act as effective breast cancer therapeutic treatments. 
4.10 Future work 
Our work in this project has provided definitive data on the direct effect of Col 3 coated fibrous 
scaffolds in promoting breast cancer cell apoptosis. Our next step would be to conduct in vitro 
specificity tests to confirm that our methods are not promoting similar responses in non-
pathologic cells, although published and preliminary data from the Volk laboratory and others 
suggest that this is extremely unlikely. It is possible that non-pathological cells differentially 
express Col 3 receptors (ex. integrins), thereby effecting the fate of such cells, i.e. probably 
limiting the pro-apoptotic effect of Col 3 on such cells.  In addition, we will compare the effect 
of Col 3- and Col 1-coated unaligned fibrous scaffolds on breast cancer cell apoptosis, to 
determine if Col 3 coating remains superior in its ability to induce apoptosis in the context of an 
unaligned scaffold. An important next step will be to shift focus to in vivo studies, where we 
would be experimenting with fibrous scaffolds with an added sacrificial component. Research 
by the Mauck lab has shown that composites containing the slow-degrading PCL and water-
soluble, sacrificial PEO (poly-ethylene oxide) can be used to selectively increase pore size of the 
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mesh, by selectively removing the sacrificial component55. This enables for enhanced cell 
infiltration and improved matrix integration. This also leads to an increase in the tensile 
properties of the engineered constructs (providing for a close imitation of the native ECM)55. In 
relation, we will also be conducting porosity analysis on our composite scaffolds to determine 
the effect of porosity on cancer cell infiltration and apoptosis. Ultimately, we will assess if these 
scaffolds promote apoptosis of microscopic residual disease in resection sites in vivo and if this 
promotion of apoptosis would be able to prevent local recurrence and ultimately metastasis. 
Based on previous research, we also predict these biomaterials will improve quality of healing 
post-surgery. Future studies will directly test this hypothesis. Additional potential avenues of 
research also include whether Col 3-based biomaterials (in other forms) would be prevent the 
progression of benign cancer into more aggressive types.  
The possibility that Col 3 biomaterials can eliminate microscopic disease and therefore limit 
local recurrence and ultimately metastasis provides for an exciting avenue for the treatment of 
breast cancer, particularly if able to replace more toxic therapies such as chemo- or radiation 
therapy and also maintain superior cosmetic outcomes.   
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Appendix 
 
MATLAB program for quantifying circular variance 
function [VarF]=Circular(Fetal2)%To input variance values 
Fetal2=(Fetal2.*pi./180).*2;%To convert sin and cos angle values 
for i=1:length(Fetal2)%specifying length of array 
    Cosi(i)=cos(Fetal2(i));%converting input angle into cos 
angle 
    Sini(i)=sin(Fetal2(i));converting input angle into sin angle 
end 
SumCos=(sum(Cosi)).^2;%squaring the summation of cos angle 
SumSin=(sum(Sini)).^2;%squaring the summation of sin angle 
RsqF2=SumCos+SumSin; %adding cos and sin angled 
 
RF=sqrt(RsqF2); 
Rfv=RF/length(Fetal2); 
 
VarF=1-Rfv; 
end 
 
 
 
 
 
 
